Systemic sclerosis & Raynaud's
Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort
Authors' conclusion
Continuation of nintedanib beyond 12 months, compared with discontinuation within 12 months, is associated with significant improvements in pulmonary function, biomarkers, and survival in patients with SARD-ILD-related PPF
Study context
- Population
- Consecutive patients with SARD-ILD receiving nintedanib for progressive pulmonary fibrosis, KEIO-SARD-ILD cohort, 2015–2025SSc 16, IIM 15, RA 13
- Participants
- 65 patients
- Exposure
- Nintedanib continuation for 12 months vs discontinuation within 12 months
- Outcome
- Change in %FVC
- Follow-up
- 12 months
Methodological detailsconsecutive patients, single cohort (KEIO-SARD-ILD)
- Consecutive patients
- Single cohort (KEIO-SARD-ILD)
Main finding
As reported in the abstract
Continuation
1.8 %
Discontinuation
−3.5 %
P = 0.01
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Continuation | Discontinuation | P value |
|---|---|---|---|
| Change in %FVC in the 12 months before nintedanib initiation · 12 months prior to initiation | −3.6 % | −3.8 % | P = 0.58 |
| Change in KL-6 · 12 months | −175 U/mL | 71 U/mL | P = 0.04 |
- ILD-related survival · better survival with continuation
- P = 0.02
Overall 12-month retention of nintedanib
- Retention rate
- 69.2 %
Original publication
Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort. Semin Arthritis Rheum. Published 11 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →